Jan van de Winkel co-founded Genmab in February 1999, which under his leadership, has achieved many key milestones including:
More than 20 key partnerships to create next-generation therapies,
39 investigational new drug applications for antibodies created by Genmab or with Genmab’s technologies, which have led to more than 20 investigational medicines in clinical development incorporating Genmab’s innovation,
5 approved medicines incorporating Genmab’s innovation, all receiving breakthrough therapy designation or accelerated approval,
Proprietary and partnered pipeline includes over twenty, first-in-class and best-in-class investigational therapies to tackle a variety of cancers.
Genmab is a leading international biotechnology company that specializes in the creation and development of innovative and differentiated antibody therapeutics, with the aim of transforming the lives of people with cancer.